Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

March 31, 2005

Study Completion Date

October 31, 2006

Conditions
Acute Myelogenous LeukemiaMyelodysplastic SyndromeChronic Lymphocytic Leukemia
Interventions
DRUG

Mylotarg

Starting dose 2 mg/m\^2 over 2-hour intravenous infusion on day -12.

DRUG

Fludarabine

30 mg/m\^2 will be given intravenously daily at the same time over 30 minutes on days -5, -4, -3, -2.

DRUG

Melphalan

140 mg/m\^2 will be given intravenously over 20 minutes starting 2 hours after the beginning of the fludarabine infusion on day -2.

DRUG

Anti-thymocyte globulin

Patients with an unrelated or mismatched related donor will receive 0.5 mg/kg on day -3 and 1.25 mg/Kg on days -2 and -1, following the chemotherapy.

PROCEDURE

Stem cell transplant

Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation: Infusion of blood stem cells or bone marrow cells on day 0.

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00038831 - Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS | Biotech Hunter | Biotech Hunter